576 results on '"Gao, George Fu"'
Search Results
202. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors
- Author
-
Zhang, Ji-Yuan, primary, Zhang, Zheng, additional, Wang, Xicheng, additional, Fu, Jun-Liang, additional, Yao, Jinxia, additional, Jiao, Yanmei, additional, Chen, Liangen, additional, Zhang, Hui, additional, Wei, Jianan, additional, Jin, Lei, additional, Shi, Ming, additional, Gao, George Fu, additional, Wu, Hao, additional, and Wang, Fu-Sheng, additional
- Published
- 2007
- Full Text
- View/download PDF
203. Long-Term Toxicity Studies in Canine of E10A, An Adenoviral Vector for Human Endostatin Gene
- Author
-
Huang, Bi-Jun, primary, Liu, Ran-Yi, additional, Huang, Jia-Ling, additional, Liang, Zhi-Hui, additional, Gao, George Fu, additional, Wu, Jiang-Xue, additional, and Huang, Wenlin, additional
- Published
- 2007
- Full Text
- View/download PDF
204. Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017
- Author
-
Jia, Yunfei, Niu, Sheng, Hu, Yu, Chai, Yan, Zheng, Anqi, Su, Chao, Wu, Lili, Han, Pengcheng, Han, Pu, Lu, Dan, Liu, Zhimin, Yan, Xinxin, Tian, Di, Chen, Zhihai, Qi, Jianxun, Tian, Wen-xia, Wang, Qihui, and Gao, George Fu
- Abstract
Since the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, multiple SARS-CoV-2-related viruses have been characterized, including pangolin-origin GD/1/2019 and GX/P2V/2017. Our previous study indicated that both viruses have the potential to infect humans. Here, we find that CB6 (commercial name etesevimab), a COVID-19 therapeutic monoclonal antibody (MAb) developed by our group, efficiently inhibits GD/1/2019 but not GX/P2V/2017. A total of 50 SARS-CoV-2 MAbs divided into seven groups based on their receptor-binding domain (RBD) epitopes, together with the COVID-19 convalescent sera, are systematically screened for their cross-binding and cross-neutralizing properties against GX/P2V/2017. We find that GX/P2V/2017 displays substantial immune difference from SARS-CoV-2. Furthermore, we solve two complex structures of the GX/P2V/2017 RBD with MAbs belonging to RBD-1 and RBD-5, providing a structural basis for their different antigenicity. These results highlight the necessity for broad anti-coronavirus countermeasures and shed light on potential therapeutic targets.
- Published
- 2022
- Full Text
- View/download PDF
205. ERASE: a novel nucleic-acid based antiviral mechanism
- Author
-
Gao, George Fu
- Published
- 2021
- Full Text
- View/download PDF
206. Molecular basis of cross‐species ACE2 interactions with SARS‐CoV‐2‐like viruses of pangolin origin.
- Author
-
Niu, Sheng, Wang, Jia, Bai, Bin, Wu, Lili, Zheng, Anqi, Chen, Qian, Du, Pei, Han, Pengcheng, Zhang, Yanfang, Jia, Yunfei, Qiao, Chengpeng, Qi, Jianxun, Tian, Wen‐xia, Wang, Hong‐Wei, Wang, Qihui, and Gao, George Fu
- Subjects
ANGIOTENSIN converting enzyme ,VIRUSES ,CORONAVIRUSES ,SARS-CoV-2 - Published
- 2022
- Full Text
- View/download PDF
207. The mysterious origins of the Omicron variant of SARS-CoV-2
- Author
-
Du, Pei, Gao, George Fu, and Wang, Qihui
- Published
- 2022
- Full Text
- View/download PDF
208. PD-1 up-regulation is correlated with HIV-specific memory CD8+T-cell exhaustion in typical progressors but not in long-term nonprogressors
- Author
-
Zhang, Ji-Yuan, Zhang, Zheng, Wang, Xicheng, Fu, Jun-Liang, Yao, Jinxia, Jiao, Yanmei, Chen, Liangen, Zhang, Hui, Wei, Jianan, Jin, Lei, Shi, Ming, Gao, George Fu, Wu, Hao, and Wang, Fu-Sheng
- Abstract
The immunoreceptor PD-1 is significantly up-regulated on exhausted CD8+T cells during chronic viral infections such as HIV-1. However, it remains unknown whether PD-1 expression on CD8+T cells differs between typical progressors (TPs) and long-term nonprogressors (LTNPs). In this report, we examined PD-1 expression on HIV-specific CD8+T cells from 63 adults with chronic HIV infection. We found that LTNPs exhibited functional HIV-specific memory CD8+T cells with markedly lower PD-1 expression. TPs, in contrast, showed significantly up-regulated PD-1 expression that was closely correlated with a reduction in CD4 T-cell number and an elevation in plasma viral load. Importantly, PD-1 up-regulation was also associated with reduced perforin and IFN-γ production, as well as decreased HIV-specific effector memory CD8+T-cell proliferation in TPs but not LTNPs. Blocking PD-1/PD-L1 interactions efficiently restored HIV-specific CD8+T-cell effector function and proliferation. Taken together, these findings confirm the hypothesis that high PD-1 up-regulation mediates HIV-specific CD8+T-cell exhaustion. Blocking the PD-1/PD-L1 pathway may represent a new therapeutic option for this disease and provide more insight into immune pathogenesis in LTNPs.
- Published
- 2007
- Full Text
- View/download PDF
209. Demographic features of identified PLWHA infected through commercial and nonmarital noncommercial heterosexual contact in China from 2015 to 2018: a retrospective cross-sectional study.
- Author
-
Dong, Zhilong, Ma, Liying, Cai, Chang, Gao, George Fu, and Lyu, Fan
- Subjects
HIV infection transmission ,CROSS-sectional method ,AIDS prevention ,HETEROSEXUALS ,DEMOGRAPHIC characteristics - Abstract
Background: Understanding the demographic characteristics of people living with HIV/AIDS (PLWHA) infected through commercial heterosexual contact (CHC) or nonmarital noncommercial heterosexual contact (NMNCHC) is important for HIV/AIDS prevention and control. Methods: Cases reported through the Chinese HIV/AIDS Case Reporting System (CRS) from 2015 to 2018 were analyzed. A descriptive and preliminary inferential analysis were performed for those demographic characteristics deemed of interest. Results: Overall, 523,121 identified PLWHA between 2015 and 2018 in the CRS were analyzed. The constituent ratio of heterosexual transmission increased from 66.25% in 2015 to 71.48% in 2018. The proportion of CHC heterosexual transmission decreased from 40.18% in 2015 to 37.99% in 2018, while that of NMNCHC increased from 46.33% in 2015 to 49.02% in 2018. PLWHA infected through NMNCHC were significantly younger than those who were infected through CHC (Student's t test, P < 0.0001), with an average age gap ranging from 5.63 (2015) to 7.46 (2018) years, and the average age of both groups increased annually. The frequency of newly identified PLWHA who were infected through CHC had a remarkable increase among the ages of 65 and above. Gender distribution was significantly different between CHC and NMNCHC (χ
2 = 8909.00(2015), 9941.90(2016), 11,004.00 (2017), 12,836.00(2018), all P < 0.0001), and the ratio of men to women in the NMCHC group was 1.50:1 (2015), 1.51:1 (2016), 1.54:1 (2017), and 1.52:1 (2018), while in the commercial heterosexual contact (CHC) group, these ratios were 11.45:1 (2015), 12.08:1 (2016), 12.53:1 (2017), and 13.28:1 (2018). Marital status was significantly different between CHC and NMNCHC (χ2 = 94.67 (2015), 109.88(2016), 58.18(2017), 152.38(2018), all P < 0.0001). As the educational level improved, the proportion of NMNCHC also increased (Cochran - Armitage test, P < 0.0001). Conclusions: We found that heterosexual transmission was the primary mode of HIV transmission in China from 2015 to 2018. PLWHA infected through CHC and NMNCHC had different characteristics in age, gender, marital status, and educational level. The frequency of PLWHA infected through CHC increased substantially in the age group of 65 and above. This study provides useful baseline data for future studies on the heterosexual transmission of HIV in China. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
210. Immune suppression in the early stage of COVID-19 disease.
- Author
-
Tian, Wenmin, Zhang, Nan, Jin, Ronghua, Feng, Yingmei, Wang, Siyuan, Gao, Shuaixin, Gao, Ruqin, Wu, Guizhen, Tian, Di, Tan, Wenjie, Chen, Yang, Gao, George Fu, and Wong, Catherine C. L.
- Subjects
COVID-19 ,IMMUNOSUPPRESSION ,PANDEMICS ,VIRUS diseases ,COMMUNICABLE diseases ,PROTEOMICS - Abstract
The outbreak of COVID-19 has become a worldwide pandemic. The pathogenesis of this infectious disease and how it differs from other drivers of pneumonia is unclear. Here we analyze urine samples from COVID-19 infection cases, healthy donors and non-COVID-19 pneumonia cases using quantitative proteomics. The molecular changes suggest that immunosuppression and tight junction impairment occur in the early stage of COVID-19 infection. Further subgrouping of COVID-19 patients into moderate and severe types shows that an activated immune response emerges in severely affected patients. We propose a two-stage mechanism of pathogenesis for this unusual viral infection. Our data advance our understanding of the clinical features of COVID-19 infections and provide a resource for future mechanistic and therapeutics studies. How COVID-19 pathology differs from other drivers of pneumonia is unclear. Here the authors analyze urine from patients with COVID-19 and identify an immunosuppressive protein expression pattern that is distinct from the pattern in healthy individuals or patients with non-COVID-19 pneumonia. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
211. Cryo-EM structure of the varicella-zoster virus A-capsid.
- Author
-
Sun, Junqing, Liu, Congcong, Peng, Ruchao, Zhang, Fu-Kun, Tong, Zhou, Liu, Sheng, Shi, Yi, Zhao, Zhennan, Zeng, Wen-Bo, Gao, George Fu, Shen, Hong-Jie, Yang, Xiaoming, Luo, Minhua, Qi, Jianxun, and Wang, Peiyi
- Subjects
VARICELLA-zoster virus ,CAPSIDS ,HERPES zoster ,ANTIVIRAL agents ,VARICELLA-zoster virus diseases ,HERPESVIRUS diseases ,HERPESVIRUSES ,TARGETED drug delivery - Abstract
Varicella-zoster virus (VZV), a member of the Alphaherpesvirinae subfamily, causes severe diseases in humans of all ages. The viral capsids play critical roles in herpesvirus infection, making them potential antiviral targets. Here, we present the 3.7-Å-resolution structure of the VZV A-capsid and define the molecular determinants underpinning the assembly of this complicated viral machinery. Overall, the VZV capsid has a similar architecture to that of other known herpesviruses. The major capsid protein (MCP) assembles into pentons and hexons, forming extensive intra- and inter-capsomer interaction networks that are further secured by the small capsid protein (SCP) and the heterotriplex. The structure reveals a pocket beneath the floor of MCP that could potentially be targeted by antiviral inhibitors. In addition, we identified two alphaherpesvirus-specific structural features in SCP and Tri1 proteins. These observations highlight the divergence of different herpesviruses and provide an important basis for developing antiviral drugs. Varicella-zoster virus (VZV) is the causative agent of chickenpox and herpes zoster (shingles). Cryo-EM structure of VZV capsid provides insights into the capsid assembly and reveals a pocket that could potentially be targeted by antiviral drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
212. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
- Author
-
Fu, Lifeng, Ye, Fei, Feng, Yong, Yu, Feng, Wang, Qisheng, Wu, Yan, Zhao, Cheng, Sun, Huan, Huang, Baoying, Niu, Peihua, Song, Hao, Shi, Yi, Li, Xuebing, Tan, Wenjie, Qi, Jianxun, and Gao, George Fu
- Subjects
SARS-CoV-2 ,COVID-19 ,RNA polymerases ,COVID-19 pandemic ,PROTEOLYTIC enzymes ,REMDESIVIR - Abstract
COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (M
pro , also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target. Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting Mpro . Moreover, combined application of GC376 with Remdesivir, a nucleotide analogue that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect. Further structural analysis reveals binding of both inhibitors to the catalytically active side of SARS-CoV-2 protease Mpro as main mechanism of inhibition. Our findings may provide critical information for the optimization and design of more potent inhibitors against the emerging SARS-CoV-2 virus. Coronavirus main protease is essential for viral polyprotein processing and maturation. Here Fu et al. report efficient inhibition of SARS-CoV-2 replication using two inhibitors - Boceprevir and GC376 - targeting the active site of the main viral protease. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
213. Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex.
- Author
-
Du, Pei, Huang, Lei, Fang, Yi, Zhao, Fanfan, Li, Qianyun, Ma, Xuehui, Li, Ruiqi, Chen, Qian, Shen, Haifa, Wang, Qihui, Li, Hangwen, and Gao, George Fu
- Subjects
- *
SARS-CoV-2 , *MICE , *TRANSGENIC mice , *COVID-19 , *SARS-CoV-2 Omicron variant , *CHIMERIC proteins , *BOOSTER vaccines , *HETERODIMERS - Abstract
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, continues to mutate and generates new variants with increasingly severe immune escape, urging the upgrade of COVID-19 vaccines. Here, based on a similar dimeric RBD design as our previous ZF2001 vaccine, we developed a novel broad-spectrum COVID-19 mRNA vaccine, SWIM516, with chimeric Delta-BA.2 RBD dimer delivered by lipopolyplex (LPP). Unlike the popular lipid nanoparticle (LNP), this LPP-delivered mRNA expresses only in the injection site, which avoids potential toxicity to the liver. We demonstrated the broad-spectrum humoral and cellular immunogenicity of this vaccine to Delta and Omicron sub-variants in naïve mice and as booster shots. When challenged with Delta or Omicron live virus, vaccinated hACE2 transgenic mice and rhesus macaques were both protected, displaying significantly reduced viral loads and markedly relieved pathological damages. We believe the SWIM516 vaccine qualifies as a candidate for the next-generation broad-spectrum COVID-19 vaccine. Author summary: mRNA vaccines have demonstrated their advantages in immunogenicity and development speed during the coronavirus disease 2019 (COVID-19) pandemic. However, the significant immune escape caused by the evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented a considerable challenge to the effectiveness of COVID-19 vaccines. Moreover, concerns have arisen about the potential liver toxicity associated with the lipid nanoparticles (LNP) used in approved mRNA vaccines, raising questions about their safety. To address these challenges, we have developed the SWIM516 vaccine, which utilizes a chimeric Delta-BA.2 RBD dimer immunogen to provide broad-spectrum protection and a lipopolyplex (LPP) delivery system to enhance safety. This vaccine has demonstrated its ability to induce broad-spectrum immunogenicity in mice and offers protection to both mice and monkeys when exposed to live SARS-CoV-2 challenges, qualifying it as a next-generation broad-spectrum COVID-19 vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
214. Brazil and China, creating healthy spaces for all.
- Author
-
Costa Lobato, André, Morel, Carlos Medicis, and Gao, George Fu
- Subjects
- BRAZIL, CHINA
- Published
- 2023
- Full Text
- View/download PDF
215. A Mycobacterium tuberculosis surface protein recruits ubiquitin to trigger host xenophagy.
- Author
-
Chai, Qiyao, Wang, Xudong, Qiang, Lihua, Zhang, Yong, Ge, Pupu, Lu, Zhe, Zhong, Yanzhao, Li, Bingxi, Wang, Jing, Zhang, Lingqiang, Zhou, Dawang, Li, Wei, Dong, Wenzhu, Pang, Yu, Gao, George Fu, and Liu, Cui Hua
- Abstract
Ubiquitin-mediated xenophagy, a type of selective autophagy, plays crucial roles in host defense against intracellular pathogens including Mycobacterium tuberculosis (Mtb). However, the exact mechanism by which host ubiquitin targets invaded microbes to trigger xenophagy remains obscure. Here we show that ubiquitin could recognize Mtb surface protein Rv1468c, a previously unidentified ubiquitin-binding protein containing a eukaryotic-like ubiquitin-associated (UBA) domain. The UBA-mediated direct binding of ubiquitin to, but not E3 ubiquitin ligases-mediated ubiquitination of, Rv1468c recruits autophagy receptor p62 to deliver mycobacteria into LC3-associated autophagosomes. Disruption of Rv1468c-ubiquitin interaction attenuates xenophagic clearance of Mtb in macrophages, and increases bacterial loads in mice with elevated inflammatory responses. Together, our findings reveal a unique mechanism of host xenophagy triggered by direct binding of ubiquitin to the pathogen surface protein, and indicate a diplomatic strategy adopted by Mtb to benefit its persistent intracellular infection through controlling intracellular bacterial loads and restricting host inflammatory responses. Ubiquitin (Ub)-mediated xenophagy is important in defense against Mycobacterium tuberculosis (Mtb). Here, Chai et al. describe autophagy triggering by Ub binding to the Mtb surface protein Rv1468c, and show that its deletion leads to increased bacterial loads and hyperinflammatory responses in mice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
216. Insights into the inhibition mechanisms of MERS-CoV and SARS-CoV2 papain-like proteases by inhibitors from Crinum distichum: In vitro and in silico analysis.
- Author
-
Kouam, Arnaud Fondjo, Mabou, Florence Déclaire, Fu, Lifeng, Koagne, Roméol Romain, Li, Yan, Owona, Brice Ayissi, Zeuko'o, Elisabeth Menkem, Fepa, Armelle Gaelle Kwesseu, Galani, Borris Rosnay Tietcheu, Reyes, Fernando, Njayou, Frédéric Nico, Moundipa, Paul Fewou, and Gao, George Fu
- Subjects
- *
SARS-CoV-2 , *MERS coronavirus , *CORONAVIRUS diseases , *COVID-19 , *CORONAVIRUSES - Abstract
• Five compounds: (2 S)−4´,7-dimethoxyflavan (CDS1), (2 S)−4´‑hydroxy-7-methoxyflavan (CDS2), hippadine (CDS3), (2 R)−4´‑hydroxy-5,7-dimethoxyflavan (CDS4) and hippacine (CDS5) were isolated from C. distichum. • The compounds inhibit the proteolytic and the deubiquitinating activities of the papain-like protease of two coronavirus species: Mers-CoV and Sars-CoV2. • The studied compounds exert their inhibitory effect through competitive and non-competitive inhibition mechanisms. • These compounds also induced the instability of the enzymes by reducing their melting temperature. Highly pathogenic coronaviruses, including the Middle East Respiratory Syndrome Coronavirus (Mers-CoV) and Severe Acute Respiratory Syndrome Coronavirus-2 (Sars-CoV2), have recently emerged and represent a serious threat to global health. Accordingly, a search for potent inhibitors against coronavirus diseases is warranted. Therefore, this study aimed at identifying potential inhibitors from Crinum distichum against the papain-like protease (PLpro), an important antiviral target due to its essential role in viral replication. A bacterial expression system was used for the recombinant expression of Mers-CoV-PLpro and Sars-CoV2-PLpro which was used to assess the inhibitory effect of compounds isolated from C. distichum against their proteolytic and deubiquitinating (DUB) activities. Then, the inhibition mechanism of hit compounds was determined through enzyme kinetic studies. Protein-ligand stability was assessed by Differential Scanning Fluorometry and Molecular docking was used to predict the possible molecular interactions. Five compounds, namely (2 S)-4´,7-dimethoxyflavan (CDS1), (2 S)-4´‑hydroxy-7-methoxyflavan (CDS2), Hippadine (CDS3), (2 R)-4´‑hydroxy-5,7-dimethoxyflavan (CDS4) and Hippacine (CDS5) were tested in this study. They markedly inhibited both the proteolytic and deubiquitinating activities of CoV-PLpro. Their IC 50 values were in the low micromolar range. The most potent inhibitors were CDS3 and CDS4, with IC 50 values of 9.28 and 6.45 µM, and 11.63 and 6.10 µM against the proteolytic and DUB activities of Mers-CoV-PLpro and Sars-CoV2-PLpro, respectively. They exert their inhibitory effect through competitive and non-competitive inhibition mechanisms. These compounds induced the instability of the enzymes by reducing their melting temperature and molecular docking analysis revealed several molecular interactions between the compounds and various amino acids of the enzymes. Overall, our findings suggest C. distichum active constituents to be promising candidates for development into potential inhibitors against coronavirus. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
217. Spatially resolved transcriptomics reveals distinct pulmonary immune responses during influenza virus and SARS-CoV-2 infections.
- Author
-
Zhao, Min, Shao, Fei, Liu, Zhen, Ma, Jiangwen, Yu, Dou, Zhang, Hangjie, Dai, Lianpan, Xu, Kun, Zhao, Xin, Zheng, Mengli, Gao, George Fu, and Wang, Shuo
- Subjects
- *
VIRUS diseases , *TRANSCRIPTOMES , *INFLUENZA viruses , *IMMUNE response , *INFLUENZA A virus , *SARS-CoV-2 - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
218. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities.
- Author
-
Hu, Shixiong, Wu, Chunli, Wu, Xinkai, Ma, Xuehui, Shu, Chang, Chen, Qian, Zheng, Anqi, Yang, Huiting, Lu, Jian, Du, Pei, Gao, George Fu, and Wang, Qihui
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *SARS-CoV-2 Omicron variant , *SEROTYPES , *IMMUNOGLOBULINS - Abstract
[Display omitted] The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a significant number of variants, particularly with the emergence of Omicron with many sub-variants. These variants have exhibited increased immune escape, leading to reduced efficacy of existing vaccines and therapeutic antibodies. Given the diminished cross-neutralization observed among these variants, it is plausible that SARS-CoV-2 has developed multiple serotypes. As the major antigenic site, the receptor-binding domain (RBD) of viral spike (S) protein was chosen for serotyping. We selected 23 representative variants, including pre-Omicron variants and Omicron sub-variants, and classified them into five serotypes based on systematic evaluation of the antigenicities of their RBDs. Each serotype includes several genetically distinct variants. Serotype-I encompasses all pre-Omicron variants (with two subtypes), while the remaining four serotypes are all comprised of Omicron sub-variants at different stages of evolution. We propose that these serotypes can serve as a foundation for rapid classification of newly emerging SARS-CoV-2 variants, and guide the development of future broad-spectrum vaccines and neutralizing antibodies against the coronavirus disease 2019 (COVID-19). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
219. Discovery and identification of a novel canine coronavirus causing a diarrhea outbreak in Vulpes.
- Author
-
Liu, Yuting, Deng, Yao, Niu, Sheng, Zhu, Na, Song, Jingdong, Zhang, Xiaoshuang, Su, Weiting, Nie, Wenhui, Lu, Roujian, Irwin, David M., Gao, George Fu, Wang, Wenling, Wang, Qihui, Tan, Wenjie, and Zhang, Shuyi
- Subjects
- *
SARS-CoV-2 , *BATS , *ANIMAL health , *ALANINE aminopeptidase , *RNA replicase , *DOMESTIC animals , *IDENTIFICATION - Abstract
Cross-species transmission of viruses from wildlife animal reservoirs, such as bats, poses a threat to human and domestic animal health. Previous studies have shown that domestic animals have important roles as intermediate hosts, enabling the transmission of genetically diverse coronaviruses from natural hosts to humans. Here, we report the identification and characterization of a novel canine coronavirus (VuCCoV), which caused an epidemic of acute diarrhea in Vulpes (foxes) in Shenyang, China. The epidemic started on November 8, 2019, and caused more than 39,600 deaths by January 1, 2022. Full-length viral genomic sequences were obtained from 15 foxes with diarrhea at the early stage of this outbreak. The VuCCoV genome shared more than 90% nucleotide identity with canine coronavirus (CCoV) for three of the four structural genes, with the S gene showing a larger amount of divergence. In addition, 67% (10/15) of the VuCCoV genomes contained an open reading frame (ORF3) gene, which was previously only detected in CCoV-I genomes. Notably, VuCCoV had only two to three amino acid differences at the partial RNA-dependent RNA polymerase (RdRp) level to bat CoV, suggesting a close genetic relationship. Therefore, these novel VuCCoV genomes represent a previously unsampled lineage of CCoVs. We also show that the VuCCoV spike protein binds to canine and fox aminopeptidase N (APN), which may allow this protein to serve as an entry receptor. In addition, cell lines were identified that are sensitive to VuCCoV using a pseudovirus system. These data highlight the importance of identifying the diversity and distribution of coronaviruses in domestic animals, which could mitigate future outbreaks that could threaten livestock, public health, and economic growth. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
220. A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses.
- Author
-
Wang, Xiaoyun, Xie, Yufeng, Liu, Honghui, Lei, Wenwen, Xu, Ke, Wu, Lili, Fan, Ruiwen, Wu, Guizhen, Gao, George Fu, and Wang, Qihui
- Published
- 2023
- Full Text
- View/download PDF
221. Author Correction: Metagenome-assembled genomes and gene catalog from the chicken gut microbiome aid in deciphering antibiotic resistomes.
- Author
-
Feng, Yuqing, Wang, Yanan, Zhu, Baoli, Gao, George Fu, Guo, Yuming, and Hu, Yongfei
- Published
- 2022
- Full Text
- View/download PDF
222. Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2.
- Author
-
Hu, Songtao, Han, Pu, Wang, Meiyu, Cao, Xiaoqing, Liu, Hao, Zhang, Shuailong, Zhang, Shuijun, Liu, Jun, Han, Yi, Xiao, Jinhe, Chen, Qiang, Miao, Kai, Qi, Jianxun, Tan, Shuguang, Gao, George Fu, and Wang, Han
- Subjects
- *
IMMUNE recognition , *LIGANDS (Chemistry) , *IMMUNE checkpoint proteins , *NECTINS , *CRYSTAL structure , *LIGAND binding (Biochemistry) - Abstract
Nectin and nectin-like (Necl) co-receptor axis, comprised of receptors DNAM-1, TIGIT, CD96, PVRIG, and nectin/Necl ligands, is gaining prominence in immuno-oncology. Within this axis, the inhibitory receptor PVRIG recognizes Nectin-2 with high affinity, but the underlying molecular basis remains unknown. By determining the crystal structure of PVRIG in complex with Nectin-2, we identified a unique CC' loop in PVRIG, which complements the double-lock-and-key binding mode and contributes to its high affinity for Nectin-2. The association of the corresponding charged residues in the F-strands explains the ligand selectivity of PVRIG toward Nectin-2 but not for Necl-5. Moreover, comprehensive comparisons of the binding capacities between co-receptors and ligands provide innovative insights into the intra-axis immunoregulatory mechanism. Taken together, these findings broaden our understanding of immune recognition and regulation mediated by nectin/Necl co-receptors and provide a rationale for the development of immunotherapeutic strategies targeting the nectin/Necl axis. [Display omitted] • A unique CC' loop in PVRIG complements the double-lock-and-key binding mode to Nectin-2 • The PVRIG CC' loop contributes to high affinity binding of Nectin-2 • Charged residues central to the binding interface contribute to ligand selectivity • Comprehensive analysis of the interactions within the nectin/Necl co-receptor axis Hu et al. determined the crystal structure of the immune receptor PVRIG bound to Nectin-2. These findings contribute to a better understanding of immune recognition and immunoregulation within nectin/Necl co-receptor axis and provide the structural basis for further therapeutic development and target selection in immune checkpoint therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
223. Molecular biological and immunological studies of tick-borne flaviviruses
- Author
-
Gao, George Fu
- Subjects
- 572.8, Genetics
- Published
- 1995
224. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
- Author
-
Xia, ShengLi, Zhang, YunTao, Wang, YanXia, Wang, Hui, Yang, YunKai, Gao, George Fu, Tan, WenJie, Wu, GuiZhen, Xu, Miao, Lou, ZhiYong, Huang, WeiJin, Xu, WenBo, Huang, BaoYing, Wang, Wei, Zhang, Wei, Li, Na, Xie, ZhiQiang, Zhu, Xiujuan, Ding, Ling, and You, WangYang
- Subjects
- *
COVID-19 vaccines , *IMMUNE response , *VACCINATION of children , *SARS-CoV-2 - Abstract
Background: Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control. For further evaluation of the inactivated COVID-19 vaccine candidate BBIBP-CorV, we assessed the safety and immunogenicity of BBIBP-CorV in participants aged 3-17 years.Methods: A randomised, double-blind, controlled, phase 1/2 trial was done at Shangqiu City Liangyuan District Center for Disease Control and Prevention in Henan, China. In phases 1 and 2, healthy participants were stratified according to age (3-5 years, 6-12 years, or 13-17 years) and dose group. Individuals with a history of SARS-CoV-2 or SARS-CoV infection were excluded. All participants were randomly assigned, using stratified block randomisation (block size eight), to receive three doses of 2 μg, 4 μg, or 8 μg of vaccine or control (1:1:1:1) 28 days apart. The primary outcome, safety, was analysed in the safety set, which consisted of participants who had received at least one vaccination after being randomly assigned, and had any safety evaluation information. The secondary outcomes were geometric meant titre (GMT) of the neutralising antibody against infectious SARS-CoV-2 and were analysed based on the full analysis set. This study is registered with www.chictr.org.cn, ChiCTR2000032459, and is ongoing.Findings: Between Aug 14, 2020, and Sept 24, 2020, 445 participants were screened, and 288 eligible participants were randomly assigned to vaccine (n=216, 24 for each dose level [2/4/8 μg] in each of three age cohorts [3-5, 6-12, and 13-17 years]) or control (n=72, 24 for each age cohort [3-5, 6-12, and 13-17 years]) in phase 1. In phase 2, 810 participants were screened and 720 eligible participants were randomly assigned and allocated to vaccine (n=540, 60 for each dose level [2/4/8 μg] in each of three age cohorts [3-5, 6-12, and 13-17 years]) or control (n=180, 60 for each age cohort [3-5, 6-12, and 13-17 years]). The most common injection site adverse reaction was pain (ten [4%] 251 participants in all vaccination groups of the 3-5 years cohort; 23 [9·1%] of 252 participants in all vaccination groups and one [1·2%] of 84 in the control group of the 6-12 years cohort; 20 [7·9%] of 252 participants in all vaccination groups of the 13-17 years cohort). The most common systematic adverse reaction was fever (32 [12·7%] of 251 participants in all vaccination groups and six [7·1%] of 84 participants in the control group of the 3-5 years cohort; 13 [5·2%] of 252 participants in the vaccination groups and one [1·2%] of 84 in the control group of the 6-12 years cohort; 26 [10·3%] of 252 participants in all vaccination groups and eight [9·5%] of 84 in the control group of the 13-17 years cohort). Adverse reactions were mostly mild to moderate in severity. The neutralising antibody GMT against the SARS-CoV-2 virus ranged from 105·3 to 180·2 in the 3-5 years cohort, 84·1 to 168·6 in the 6-12 years cohort, and 88·0 to 155·7 in the 13-17 years cohort on day 28 after the second vaccination; and ranged from 143·5 to 224·4 in the 3-5 years cohort, 127 to 184·8 in the 6-12 years cohort, and 150·7 to 199 in the 13-17 years cohort on day 28 after the third vaccination.Interpretation: The inactivated COVID-19 vaccine BBIBP-CorV is safe and well tolerated at all tested dose levels in participants aged 3-17 years. BBIBP-CorV also elicited robust humoral responses against SARS-CoV-2 infection after two doses. Our findings support the use of a 4 μg dose and two-shot regimen BBIBP-CorV in phase 3 trials in the population younger than 18 years to further ascertain its safety and protection efficacy against COVID-19.Funding: National Program on Key Research Project of China, National Mega projects of China for Major Infectious Diseases, National Mega Projects of China for New Drug Creation, and Beijing Science and Technology Plan.Translation: For the Chinese translation of the abstract see Supplementary Materials section. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
225. Metagenome-assembled genomes and gene catalog from the chicken gut microbiome aid in deciphering antibiotic resistomes.
- Author
-
Feng, Yuqing, Wang, Yanan, Zhu, Baoli, Gao, George Fu, Guo, Yuming, and Hu, Yongfei
- Subjects
- *
GUT microbiome , *GLYCOSIDASES , *MICROBIAL genomes , *METAGENOMICS , *GENOMES , *LACTIC acid bacteria , *ANTIBIOTICS , *SHOTGUN sequencing - Abstract
Gut microbial reference genomes and gene catalogs are necessary for understanding the chicken gut microbiome. Here, we assembled 12,339 microbial genomes and constructed a gene catalog consisting of ~16.6 million genes by integrating 799 public chicken gut microbiome samples from ten countries. We found that 893 and 38 metagenome-assembled genomes (MAGs) in our dataset were putative novel species and genera, respectively. In the chicken gut, Lactobacillus aviarius and Lactobacillus crispatus were the most common lactic acid bacteria, and glycoside hydrolases were the most abundant carbohydrate-active enzymes (CAZymes). Antibiotic resistome profiling results indicated that Chinese chicken samples harbored a higher relative abundance but less diversity of antimicrobial resistance genes (ARGs) than European samples. We also proposed the effects of geography and host species on the gut resistome. Our study provides the largest integrated metagenomic dataset from the chicken gut to date and demonstrates its value in exploring chicken gut microbial genes. Feng et al. include genome recovery and data analysis of large number of chicken gut metagenomic datasets which significantly expands the reference genomes available from the chicken gut microbial communities, and catalog the genes prevalent in the gut systems. They further depict the countryspecific chicken gut antibiotic resistomes and the effects of geography and host species on the gut resistome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
226. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
- Author
-
Xia, Shengli, Zhang, Yuntao, Wang, Yanxia, Wang, Hui, Yang, Yunkai, Gao, George Fu, Tan, Wenjie, Wu, Guizhen, Xu, Miao, Lou, Zhiyong, Huang, Weijin, Xu, Wenbo, Huang, Baoying, Wang, Huijuan, Wang, Wei, Zhang, Wei, Li, Na, Xie, Zhiqiang, Ding, Ling, and You, Wangyang
- Subjects
- *
SARS-CoV-2 , *COVID-19 pandemic , *ANTIBODY titer , *COVID-19 , *VACCINES - Abstract
Background: The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates. We aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, in humans.Methods: We did a randomised, double-blind, placebo-controlled, phase 1/2 trial at Shangqiu City Liangyuan District Center for Disease Control and Prevention in Henan Province, China. In phase 1, healthy people aged 18-80 years, who were negative for serum-specific IgM/IgG antibodies against SARS-CoV-2 at the time of screening, were separated into two age groups (18-59 years and ≥60 years) and randomly assigned to receive vaccine or placebo in a two-dose schedule of 2 μg, 4 μg, or 8 μg on days 0 and 28. In phase 2, healthy adults (aged 18-59 years) were randomly assigned (1:1:1:1) to receive vaccine or placebo on a single-dose schedule of 8 μg on day 0 or on a two-dose schedule of 4 μg on days 0 and 14, 0 and 21, or 0 and 28. Participants within each cohort were randomly assigned by stratified block randomisation (block size eight) and allocated (3:1) to receive vaccine or placebo. Group allocation was concealed from participants, investigators, and outcome assessors. The primary outcomes were safety and tolerability. The secondary outcome was immunogenicity, assessed as the neutralising antibody responses against infectious SARS-CoV-2. This study is registered with www.chictr.org.cn, ChiCTR2000032459.Findings: In phase 1, 192 participants were enrolled (mean age 53·7 years [SD 15·6]) and were randomly assigned to receive vaccine (2 μg [n=24], 4 μg [n=24], or 8 μg [n=24] for both age groups [18-59 years and ≥60 years]) or placebo (n=24). At least one adverse reaction was reported within the first 7 days of inoculation in 42 (29%) of 144 vaccine recipients. The most common systematic adverse reaction was fever (18-59 years, one [4%] in the 2 μg group, one [4%] in the 4 μg group, and two [8%] in the 8 μg group; ≥60 years, one [4%] in the 8 μg group). All adverse reactions were mild or moderate in severity. No serious adverse event was reported within 28 days post vaccination. Neutralising antibody geometric mean titres were higher at day 42 in the group aged 18-59 years (87·7 [95% CI 64·9-118·6], 2 μg group; 211·2 [158·9-280·6], 4 μg group; and 228·7 [186·1-281·1], 8 μg group) and the group aged 60 years and older (80·7 [65·4-99·6], 2 μg group; 131·5 [108·2-159·7], 4 μg group; and 170·87 [133·0-219·5], 8 μg group) compared with the placebo group (2·0 [2·0-2·0]). In phase 2, 448 participants were enrolled (mean age 41·7 years [SD 9·9]) and were randomly assigned to receive the vaccine (8 μg on day 0 [n=84] or 4 μg on days 0 and 14 [n=84], days 0 and 21 [n=84], or days 0 and 28 [n=84]) or placebo on the same schedules (n=112). At least one adverse reaction within the first 7 days was reported in 76 (23%) of 336 vaccine recipients (33 [39%], 8 μg day 0; 18 [21%], 4 μg days 0 and 14; 15 [18%], 4 μg days 0 and 21; and ten [12%], 4 μg days 0 and 28). One placebo recipient in the 4 μg days 0 and 21 group reported grade 3 fever, but was self-limited and recovered. All other adverse reactions were mild or moderate in severity. The most common systematic adverse reaction was fever (one [1%], 8 μg day 0; one [1%], 4 μg days 0 and 14; three [4%], 4 μg days 0 and 21; two [2%], 4 μg days 0 and 28). The vaccine-elicited neutralising antibody titres on day 28 were significantly greater in the 4 μg days 0 and 14 (169·5, 95% CI 132·2-217·1), days 0 and 21 (282·7, 221·2-361·4), and days 0 and 28 (218·0, 181·8-261·3) schedules than the 8 μg day 0 schedule (14·7, 11·6-18·8; all p<0·001).Interpretation: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, is safe and well tolerated at all tested doses in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients on day 42. Two-dose immunisation with 4 μg vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres than the single 8 μg dose or 4 μg dose on days 0 and 14.Funding: National Program on Key Research Project of China, National Mega projects of China for Major Infectious Diseases, National Mega Projects of China for New Drug Creation, and Beijing Science and Technology Plan. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
227. Structural Illumination of Equine MHC Class I Molecules Highlights Unconventional Epitope Presentation Manner That Is Evolved in Equine Leukocyte Antigen Alleles.
- Author
-
Shugang Yao, Jun Liu, Jianxun Qi, Rong Chen, Nianzhi Zhang, Yanjie Liu, Junya Wang, Yanan Wu, Gao, George Fu, and Chun Xia
- Subjects
- *
LENTIVIRUSES , *EPITOPES , *LEUCOCYTES , *ALLELES , *PEPTIDES , *AMINO acids , *GENETIC carriers - Abstract
MHC class I (MHC I)-restricted virus-specific CTLs are implicated as critical components in the control of this naturally occurring lentivirus and in the protective immune response to the successfully applied attenuated equine infectious anemia virus vaccine in the horse. Nevertheless, the structural basis for how the equine MHC I presents epitope peptides remains unknown. In this study, we investigated the binding of several equine infectious anemia virus-derived epitope peptides by the ability to refold recombinant molecules and by thermal stability, and then by determining the x-ray structure of five peptide-MHC I complexes: equine MHC class 1 allele (Eqca)-N*00602/Env-RW12, Eqca-N*00602/Gag-GW12, Eqca-N*00602/Rev-QWll, Eqca-N*00602/ Gag-CF9, and Eqca-N*00601/Gag-GW12. Although Eqca-N*00601 and Eqca-N*00602 differ by a single amino acid, Eqca- N*00601 exhibited a drastically different peptide presentation when binding a similar CTL epitope, Gag-GW12; the result makes the previously reported function clear to be non-cross-recognition between these two alleles. The structures plus Eqca-N*00602 complexed with a 9-mer peptide are particularly noteworthy in that we illuminated differences in apparent flexibility in the center of the epitope peptides for the complexes with Gag-GW12 as compared with Env-RW12, and a strict selection of epitope peptides with normal length. The featured preferences and unconventional presentations of long peptides by equine MHC I molecules provide structural bases to explain the exceptional anti-lentivirus immunity in the horse. We think that the beneficial reference points could serve as an initial platform for other human or animal lentiviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
228. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1.
- Author
-
Li, Linjie, Liao, Hanyi, Meng, Yumin, Li, Weiwei, Han, Pengcheng, Liu, Kefang, Wang, Qing, Li, Dedong, Zhang, Yanfang, Wang, Liang, Fan, Zheng, Zhang, Yuqin, Wang, Qiyue, Zhao, Xin, Sun, Yeping, Huang, Niu, Qi, Jianxun, and Gao, George Fu
- Subjects
- *
SARS-CoV-2 Omicron variant , *SARS-CoV-2 - Abstract
The currently circulating Omicron sub-variants are the SARS-CoV-2 strains with the highest number of known mutations. Herein, we found that human angiotensin-converting enzyme 2 (hACE2) binding affinity to the receptor-binding domains (RBDs) of the four early Omicron sub-variants (BA.1, BA.1.1, BA.2, and BA.3) follows the order BA.1.1 > BA.2 > BA.3 ≈ BA.1. The complex structures of hACE2 with RBDs of BA.1.1, BA.2, and BA.3 reveal that the higher hACE2 binding affinity of BA.2 than BA.1 is related to the absence of the G496S mutation in BA.2. The R346K mutation in BA.1.1 majorly affects the interaction network in the BA.1.1 RBD/hACE2 interface through long-range alterations and contributes to the higher hACE2 affinity of the BA.1.1 RBD than the BA.1 RBD. These results reveal the structural basis for the distinct hACE2 binding patterns among BA.1.1, BA.2, and BA.3 RBDs. [Display omitted] • Omicron BA.1.1 and BA.2 show higher binding strength to hACE2 than the prototype and BA.1 • Details in the binding interface of BA.1.1, BA.2, and BA.3.RBD with hACE2 are deciphered • R346K in BA.1.1 RBD enhances the interaction with hACE2 through long-range alterations The biochemical and structural analysis of the human angiotensin-converting enzyme-2 (ACE2, the receptor for SARS-CoV-2 viral entry) and the receptor-binding domain (RBD) of four Omicron sub-variants—BA.1, BA.1.1, BA.2, and BA.3—helps to reveal the structural basis of differences in sub-variant binding affinities and the impact of RBD mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
229. Assessment of the pathogenesis of Streptococcus suis type 2 infection in piglets for understanding streptococcal toxic shock-like syndrome, meningitis, and sequelae.
- Author
-
Bi, Yuhai, Li, Jing, Yang, Limin, Zhang, Shuang, Li, Yun, Jia, Xiaojuan, Sun, Lei, Yin, Yanbo, Qin, Chuan, Wang, Beinan, Gao, George Fu, and Liu, Wenjun
- Subjects
- *
STREPTOCOCCUS suis , *PIGLETS , *SWINE diseases , *ZOONOSES , *STREPTOCOCCAL diseases , *TOXIC shock syndrome , *MENINGITIS , *DISEASE complications , *DISEASE progression - Abstract
Streptococcus suis type 2 (SS2) is an zoonotic pathogen that had caused outbreaks in 1998 and 2005 in China. It is still not very clear how the disease progresses into the streptococcal toxic shock-like syndrome (STSLS) or meningitis, as well as the sequelae from the survivals. The present study used piglets as infection model to systematically investigate the pathogenesis of the infection caused by the SS2 strain 05ZYH33. The infected piglets showed joint swelling, lameness, and crouch at beginning, then developed into septic-like shock syndrome (SLSS) or prostration syndrome, at last the survivals showed physical activity impairment. The morbidity and mortality were 100% (71% for SLSS, 29% for prostration syndrome) and 29%, respectively. The pigs exhibiting SLSS had deep invasive infections in tissues and organs, and displayed more severe bacteremia and cytokine secretion in the bloodstream and organs than pigs with prostration syndrome. Moreover, the polymorphisms in the toll-like receptor 1 (TLR1) and TLR2 genes varied between the pigs affected with SLSS and prostration syndrome. Several lines of evidence indicated that SS2 infection progression into SLSS or relatively lighter prostration syndrome in pigs is closely related to the degrees of bacteremia and cytokine storm, which may be inherently determined by the diversity of innate immunity-associated genes. Furthermore, brain lesions, such as venous thrombosis, may directly contribute to the sequelae in human cases, were identified in the pigs. These results might help us to further understand the pathogenesis of SS2 in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
230. Strengthening the role of ethnic minority women in science and medicine in China.
- Author
-
Jiayue Hu, Fu Gao, George, Ji-Long Chen, Hu, Jiayue, Gao, George Fu, and Chen, Ji-Long
- Subjects
- *
ETHNIC groups , *LABOR mobility , *MEDICINE , *SCIENCE , *VOCATIONAL guidance , *WOMEN - Abstract
The article discusses on improving the representation of women in the fields of science and medicine in China. Topics discussed include issues related to women such as poor educational facilities, absence of high quality teaching, and domestic responsibilities; loss of opportunities in remote areas to receive higher education; and efforts by the Chinese government in order to improve educational and medical facilities in remote and underdeveloped minority areas.
- Published
- 2019
- Full Text
- View/download PDF
231. Diurnal rhythm disruptions induced by chronic unpredictable stress relate to depression-like behaviors in rats.
- Author
-
Wang, Xin-Ling, Wang, De-Quan, Jiao, Fu-Chao, Ding, Kai-Mo, Ji, Yan-Bin, Lu, Lin, Yuan, Kai, Gao, George Fu, and Li, Su-Xia
- Subjects
- *
CIRCADIAN rhythms , *MOLECULAR clock , *CHRONOBIOLOGY disorders , *ENZYME-linked immunosorbent assay , *CLOCK genes , *WESTERN immunoblotting , *RATS - Abstract
The relationship between circadian rhythms and mood disorders has been established, circadian dysregulations are believed to exacerbate the severity of mood disorders and vice versa. Although many studies on diurnal changes of clock genes in animal model of depression have been performed from the RNA level, only a few studies have been carried out from the protein level. In this study, we investigated the diurnal changes induced by chronic unpredictable stress (CUS) using various methods, including free-running wheel test, enzyme-linked immunosorbent assay (ELISA) and Western Blotting (WB). Besides, we examined the depression-like behaviors of rats by sucrose preference test (SPT) and forced swim test (FST). We found that CUS induced significant reductions in the quantity of free-running wheel activity and the amplitude of melatonin secretion rhythm. We also found that CUS induced rhythmic disruptions of clock proteins in hippocampus. Furthermore, we found that the amplitude of PER1 in CA1 was positively related to the severity of depression-like behaviors. These results suggest that stress results in both changes in circadian rhythms and in depression-like behaviors and that it is suggested that these changes are related. • This research firstly provides an evidence that CUS induced rhythmic disruptions of clock proteins in hippocampus. • This research provides an evidence that CUS induced significant reductions in the quantity of free - running wheel activity and the amplitude of melatonin secretion rhythm. • The amplitude of PER1 in CA1 was positively correlated with the severity of depression - like behaviors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
232. Structural characteristics of BtKY72 RBD bound to bat ACE2 reveal multiple key residues affecting ACE2 usage of sarbecoviruses.
- Author
-
Su C, He J, Wang L, Hu Y, Cao J, Bai B, Qi J, Gao GF, Yang M, and Wang Q
- Subjects
- Humans, Animals, Protein Domains, Severe acute respiratory syndrome-related coronavirus genetics, Severe acute respiratory syndrome-related coronavirus chemistry, Severe acute respiratory syndrome-related coronavirus enzymology, COVID-19 virology, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus metabolism, Spike Glycoprotein, Coronavirus chemistry, Receptors, Virus metabolism, Receptors, Virus chemistry, Receptors, Virus genetics, Angiotensin-Converting Enzyme 2 metabolism, Angiotensin-Converting Enzyme 2 chemistry, Angiotensin-Converting Enzyme 2 genetics, SARS-CoV-2 genetics, SARS-CoV-2 chemistry, SARS-CoV-2 metabolism, Chiroptera virology, Cryoelectron Microscopy, Protein Binding
- Abstract
Two different sarbecoviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2, have caused serious challenges to public health. Certain sarbecoviruses utilize angiotensin-converting enzyme 2 (ACE2) as their cellular receptor, whereas some do not, speculatively due to the two deletions in their receptor-binding domain (RBD). However, it remains unclear whether sarbecoviruses with one deletion in the RBD can still bind to ACE2. Here, we showed that two phylogenetically related sarbecoviruses with one deletion, BtKY72 and BM48-31, displayed a different ACE2-usage range. The cryo-electron microscopy structure of BtKY72 RBD bound to bat ACE2 identified a key residue important for the interaction between RBD and ACE2. In addition, we demonstrated that the mutations involving four types of core residues enabled the sarbecoviruses with deletion(s) to bind to human ACE2 (hACE2) and broadened the ACE2 usage of SARS-CoV-2. Our findings help predict the potential hACE2-binding ability to emerge sarbecoviruses and develop pan-sarbecovirus therapeutic agents., Importance: Many sarbecoviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), possess the ability to bind to receptor angiotensin-converting enzyme 2 (ACE2) through their receptor-binding domain (RBD). However, certain sarbecoviruses with deletion(s) in the RBD lack this capability. In this study, we investigated two closely related short-deletion sarbecoviruses, BtKY72 and BM48-31, and revealed that BtKY72 exhibited a broader ACE2-binding spectrum compared to BM48-31. Structural analysis of the BtKY72 RBD-bat ACE2 complex identifies a critical residue at position 493 contributing to these differences. Furthermore, we demonstrated that the mutations involving four core residues in the RBD enabled the sarbecoviruses with deletion(s) to bind to human ACE2 and expanded the ACE2 usage spectra of SARS-CoV-2. These findings offer crucial insights for accurately predicting the potential threat of newly emerging sarbecoviruses to human health., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
233. Additional thoughts on group A streptococci.
- Author
-
Yu D, Zheng Y, Gao GF, and Yang Y
- Subjects
- Humans, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology, Streptococcal Infections microbiology, Streptococcus pyogenes pathogenicity
- Abstract
Competing Interests: We declare no competing interests. This research was funded by the Shenzhen Key Medical Discipline Construction Fund (SZXK032), Project of the Expert Committee on Clinical Application and Drug Resistance Evaluation of Antimicrobial Drugs of the National Health Commission (KJYWZWH-OT-02-2021-06), Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (SZGSP012), Guangdong High-level Hospital Construction Fund, and National Natural Science Foundation of China (82304198). DY and YZ contributed equally.
- Published
- 2024
- Full Text
- View/download PDF
234. Structural basis for difunctional mechanism of m-AMSA against African swine fever virus pP1192R.
- Author
-
Liu R, Sun J, Li LF, Cheng Y, Li M, Fu L, Li S, Peng G, Wang Y, Liu S, Qu X, Ran J, Li X, Pang E, Qiu HJ, Wang Y, Qi J, Wang H, and Gao GF
- Abstract
The African swine fever virus (ASFV) type II topoisomerase (Topo II), pP1192R, is the only known Topo II expressed by mammalian viruses and is essential for ASFV replication in the host cytoplasm. Herein, we report the structures of pP1192R in various enzymatic stages using both X-ray crystallography and single-particle cryo-electron microscopy. Our data structurally define the pP1192R-modulated DNA topology changes. By presenting the A2+-like metal ion at the pre-cleavage site, the pP1192R-DNA-m-AMSA complex structure provides support for the classical two-metal mechanism in Topo II-mediated DNA cleavage and a better explanation for nucleophile formation. The unique inhibitor selectivity of pP1192R and the difunctional mechanism of pP1192R inhibition by m-AMSA highlight the specificity of viral Topo II in the poison binding site. Altogether, this study provides the information applicable to the development of a pP1192R-targeting anti-ASFV strategy., (© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2024
- Full Text
- View/download PDF
235. Molecular insight into the neutralization mechanism of human-origin monoclonal antibody AH100 against Hantaan virus.
- Author
-
Wang F, Liu T, Liao L, Chai Y, Qi J, Gao F, Liang M, Gao GF, and Wu Y
- Subjects
- Humans, Crystallography, X-Ray, Animals, Models, Molecular, Hemorrhagic Fever with Renal Syndrome immunology, Hemorrhagic Fever with Renal Syndrome virology, Neutralization Tests, Antibodies, Monoclonal immunology, Hantaan virus immunology, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Epitopes immunology, Epitope Mapping
- Abstract
Both Old World and New World hantaviruses are transmitted through rodents and can lead to hemorrhagic fever with renal syndrome or hantavirus cardiopulmonary syndrome in humans without the availability of specific therapeutics. The square-shaped surface spikes of hantaviruses consist of four Gn-Gc heterodimers that are pivotal for viral entry into host cells and serve as targets for the immune system. Previously, a human-derived neutralizing monoclonal antibody, AH100, demonstrated specific neutralization against the Old World hantavirus, Hantaan virus. However, the precise mode binding of this neutralizing monoclonal antibody remains unclear. In the present study, we determined the structure of the Hantaan virus Gn-AH100 antigen-binding fragment complex and identified its epitope. Crystallography revealed that AH100 targeted the epitopes on domain A and b-ribbon and E3-like domain. Epitope mapping onto a model of the higher order (Gn-Gc)
4 spike revealed its localization between neighboring Gn protomers, distinguishing this epitope as a unique site compared to the previously reported monoclonal antibodies. This study provides crucial insights into the structural basis of hantavirus neutralizing antibody epitopes, thereby facilitating the development of therapeutic antibodies.IMPORTANCEHantaan virus (HTNV) poses a significant threat to humans by causing hemorrhagic fever with renal syndrome with high mortality rates. In the absence of FDA-approved drugs or vaccines, it is urgent to develop specific therapeutics. Here, we elucidated the epitope of a human-derived neutralizing antibody, AH100, by determining the HTNV glycoprotein Gn-AH100 antigen-binding fragment (Fab) complex structure. Our findings revealed that the epitopes situated on the domain A and b-ribbon and E3-like domain of the HTNV Gn head. By modeling the complex structure in the viral lattice, we propose that AH100 neutralizes the virus by impeding conformational changes of Gn protomer, which is crucial for viral entry. Additionally, sequence analysis of all reported natural isolates indicated the absence of mutations in epitope residues, suggesting the potential neutralization ability of AH100 in diverse isolates. Therefore, our results provide novel insights into the epitope and the molecular basis of AH100 neutralization., Competing Interests: The authors declare no conflict of interest.- Published
- 2024
- Full Text
- View/download PDF
236. Coxsackievirus A10 impairs nail regeneration and induces onychomadesis by mimicking DKK1 to attenuate Wnt signaling.
- Author
-
Cui Y, Shi Q, Song P, Tong J, Cheng Z, Zhang H, Wang X, Zheng Y, Wu Y, Wan M, Li S, Zhao X, Tong Z, Yu Z, Gao S, Chen YG, and Gao GF
- Subjects
- Animals, Mice, Humans, beta Catenin metabolism, Nail Diseases metabolism, Nail Diseases virology, Nail Diseases pathology, Nails metabolism, Nails pathology, Cell Differentiation drug effects, Mice, Inbred C57BL, Hand, Foot and Mouth Disease virology, Hand, Foot and Mouth Disease metabolism, Hand, Foot and Mouth Disease pathology, Hand, Foot and Mouth Disease complications, Phosphorylation drug effects, Coxsackievirus Infections complications, Coxsackievirus Infections metabolism, Glycogen Synthase Kinase 3 beta metabolism, Pyridines pharmacology, Pyrimidines, Wnt Signaling Pathway drug effects, Low Density Lipoprotein Receptor-Related Protein-6 metabolism, Low Density Lipoprotein Receptor-Related Protein-6 genetics, Intercellular Signaling Peptides and Proteins metabolism, Intercellular Signaling Peptides and Proteins genetics
- Abstract
Coxsackievirus A10 (CV-A10) infection, a prominent cause of childhood hand-foot-and-mouth disease (HFMD), frequently manifests with the intriguing phenomenon of onychomadesis, characterized by nail shedding. However, the underlying mechanism is elusive. Here, we found that CV-A10 infection in mice could suppress Wnt/β-catenin signaling by restraining LDL receptor-related protein 6 (LRP6) phosphorylation and β-catenin accumulation and lead to onychomadesis. Mechanistically, CV-A10 mimics Dickkopf-related protein 1 (DKK1) to interact with Kringle-containing transmembrane protein 1 (KRM1), the CV-A10 cellular receptor. We further found that Wnt agonist (GSK3β inhibitor) CHIR99021 can restore nail stem cell differentiation and protect against nail shedding. These findings provide novel insights into the pathogenesis of CV-A10 and related viruses in onychomadesis and guide prognosis assessment and clinical treatment of the disease., (© 2024 Cui et al.)
- Published
- 2024
- Full Text
- View/download PDF
237. LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis.
- Author
-
Wang J, Chai Q, Lei Z, Wang Y, He J, Ge P, Lu Z, Qiang L, Zhao D, Yu S, Qiu C, Zhong Y, Li BX, Zhang L, Pang Y, Gao GF, and Liu CH
- Subjects
- Humans, Animals, Mice, Macrophages immunology, Macrophages metabolism, Receptors, Immunologic metabolism, Receptors, Immunologic genetics, Antigens, CD, Leukocyte Immunoglobulin-like Receptor B1 metabolism, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, HLA-G Antigens metabolism, HLA-G Antigens genetics, HLA-G Antigens immunology, Tuberculosis immunology, Tuberculosis microbiology, Mycobacterium tuberculosis immunology
- Abstract
Chronic infections, including Mycobacterium tuberculosis (Mtb)-caused tuberculosis (TB), can induce host immune exhaustion. However, the key checkpoint molecules involved in this process and the underlying regulatory mechanisms remain largely undefined, which impede the application of checkpoint-based immunotherapy in infectious diseases. Here, through adopting time-of-flight mass cytometry and transcriptional profiling to systematically analyze natural killer (NK) cell surface receptors, we identify leukocyte immunoglobulin like receptor B1 (LILRB1) as a critical checkpoint receptor that defines a TB-associated cell subset (LILRB1
+ NK cells) and drives NK cell exhaustion in TB. Mechanistically, Mtb-infected macrophages display high expression of human leukocyte antigen-G (HLA-G), which upregulates and activates LILRB1 on NK cells to impair their functions by inhibiting mitogen-activated protein kinase (MAPK) signaling via tyrosine phosphatases SHP1/2. Furthermore, LILRB1 blockade restores NK cell-dependent anti-Mtb immunity in immuno-humanized mice. Thus, LILRB1-HLA-G axis constitutes a NK cell immune checkpoint in TB and serves as a promising immunotherapy target., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
238. Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1.
- Author
-
Tong Z, Tong J, Lei W, Xie Y, Cui Y, Jia G, Li S, Zhang Z, Cheng Z, Xing X, Ma H, Deng L, Zhang R, Zhao X, Liu K, Wang Q, Qi J, Huang H, Song R, Su Z, Wu G, Lou J, and Gao GF
- Subjects
- Humans, Antibodies, Monoclonal immunology, Antibodies, Monoclonal pharmacology, Epitopes immunology, Protein Binding, Animals, SARS-CoV-2 immunology, Antibodies, Bispecific immunology, Antibodies, Bispecific pharmacology, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, COVID-19 immunology, COVID-19 virology, COVID-19 therapy, Spike Glycoprotein, Coronavirus immunology
- Abstract
The game between therapeutic monoclonal antibodies (mAbs) and continuously emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has favored the virus, as most therapeutic mAbs have been evaded. Addressing this challenge, we systematically explored a reproducible bispecific antibody (bsAb)-dependent synergistic effect in this study. It could effectively restore the neutralizing activity of the bsAb when any of its single mAbs is escaped by variants. This synergy is primarily attributed to the binding angle of receptor-binding domain (RBD)-5, facilitating inter-spike cross-linking and promoting cryptic epitope exposure that classical antibody cocktails cannot achieve. Furthermore, RBD-5 with RBD-2, RBD-6, and RBD-7, alongside RBD-8, also exhibit significantly enhanced effects. This study not only shifts the paradigm in understanding antibody interactions but paves the way for developing more effective therapeutic antibodies against rapidly mutating SARS-CoV-2, with Dia-19 already showing promise against emerging variants like BA.2.86, EG.5.1, and JN.1., Competing Interests: Declaration of interests G.F.G., J.L., Z.T., L.D., and H.H. are listed as inventors on patent applications for bispecific antibodies., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
239. The omicron BA.2.86 subvariant as a new serotype of SARS-CoV-2.
- Author
-
Du P, Wu C, Hu S, Fan R, Gao GF, and Wang Q
- Subjects
- Humans, SARS-CoV-2 genetics, SARS-CoV-2 immunology, COVID-19 virology, COVID-19 immunology, Serogroup
- Abstract
Competing Interests: We declare no competing interests. PD, CW, and SH contributed equally to this work. This work was supported by the National Key R&D Program of China (2022YFC2303403), the National Natural Science Foundation of China (82225021, 92269203, and 32171428), and Chinese Academy of Sciences (CAS) Young Scientists in Basic Research (YSBR-010). We thank Prof Xin Zhao for sharing the plasmids used to prepare the pseudotyped viruses. We thank the Laboratory Animal Center at the Institute of Zoology, CAS, and the Institutional Center for Shared Technology and Facilities at the Institute of Microbiology, CAS. QW and GFG initiated and coordinated the project. GFG, QW, and PD designed the experiments. CW and SH constructed the plasmids, prepared the mRNA vaccines, and performed neutralisation assays with RF to prepare the pseudotyped viruses. SH performed animal experiments. PD, CW, and SH analysed the data. PD wrote the manuscript. QW and GFG revised the manuscript.
- Published
- 2024
- Full Text
- View/download PDF
240. Molecular basis of hippopotamus ACE2 binding to SARS-CoV-2.
- Author
-
Yang R, Han P, Han P, Li D, Zhao R, Niu S, Liu K, Li S, Tian W-X, and Gao GF
- Subjects
- Animals, Humans, Betacoronavirus genetics, Betacoronavirus metabolism, Binding Sites, COVID-19 virology, COVID-19 metabolism, Cryoelectron Microscopy, Protein Binding, Angiotensin-Converting Enzyme 2 metabolism, Angiotensin-Converting Enzyme 2 chemistry, Angiotensin-Converting Enzyme 2 genetics, Artiodactyla virology, SARS-CoV-2 genetics, SARS-CoV-2 metabolism, Spike Glycoprotein, Coronavirus metabolism, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus genetics
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a wide range of hosts, including hippopotami, which are semi-aquatic mammals and phylogenetically closely related to Cetacea. In this study, we characterized the binding properties of hippopotamus angiotensin-converting enzyme 2 (hiACE2) to the spike (S) protein receptor binding domains (RBDs) of the SARS-CoV-2 prototype (PT) and variants of concern (VOCs). Furthermore, the cryo-electron microscopy (cryo-EM) structure of the SARS-CoV-2 PT S protein complexed with hiACE2 was resolved. Structural and mutational analyses revealed that L30 and F83, which are specific to hiACE2, played a crucial role in the hiACE2/SARS-CoV-2 RBD interaction. In addition, comparative and structural analysis of ACE2 orthologs suggested that the cetaceans may have the potential to be infected by SARS-CoV-2. These results provide crucial molecular insights into the susceptibility of hippopotami to SARS-CoV-2 and suggest the potential risk of SARS-CoV-2 VOCs spillover and the necessity for surveillance., Importance: The hippopotami are the first semi-aquatic artiodactyl mammals wherein SARS-CoV-2 infection has been reported. Exploration of the invasion mechanism of SARS-CoV-2 will provide important information for the surveillance of SARS-CoV-2 in hippopotami, as well as other semi-aquatic mammals and cetaceans. Here, we found that hippopotamus ACE2 (hiACE2) could efficiently bind to the RBDs of the SARS-CoV-2 prototype (PT) and variants of concern (VOCs) and facilitate the transduction of SARS-CoV-2 PT and VOCs pseudoviruses into hiACE2-expressing cells. The cryo-EM structure of the SARS-CoV-2 PT S protein complexed with hiACE2 elucidated a few critical residues in the RBD/hiACE2 interface, especially L30 and F83 of hiACE2 which are unique to hiACE2 and contributed to the decreased binding affinity to PT RBD compared to human ACE2. Our work provides insight into cross-species transmission and highlights the necessity for monitoring host jumps and spillover events on SARS-CoV-2 in semi-aquatic/aquatic mammals., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
241. Injectable Hydrogel Mucosal Vaccine Elicits Protective Immunity against Respiratory Viruses.
- Author
-
Fu W, Guo M, Zhou X, Wang Z, Sun J, An Y, Guan T, Hu M, Li J, Chen Z, Ye J, Gao X, Gao GF, Dai L, Wang Y, and Chen C
- Subjects
- Animals, Mice, Mice, Inbred BALB C, Female, Humans, Mice, Inbred C57BL, Hydrogels chemistry, Administration, Intranasal, Immunity, Mucosal drug effects, Nasal Mucosa immunology
- Abstract
Intranasal vaccines, eliciting mucosal immune responses, can prevent early invasion, replication, and transmission of pathogens in the respiratory tract. However, the effective delivery of antigens through the nasal barrier and boosting of a robust systematic and mucosal immune remain challenges in intranasal vaccine development. Here, we describe an intranasally administered self-healing hydrogel vaccine with a reversible strain-dependent sol-gel transition by precisely modulating the self-assembly processes between the natural drug rhein and aluminum ions. The highly bioadhesive hydrogel vaccine enhances antigen stability and prolongs residence time in the nasal cavity and lungs by confining the antigen to the surface of the nasal mucosa, acting as a "mucosal mask". The hydrogel also stimulates superior immunoenhancing properties, including antigen internalization, cross-presentation, and dendritic cell maturation. Furthermore, the formulation recruits immunocytes to the nasal mucosa and nasal-associated lymphoid tissue (NALT) while enhancing antigen-specific humoral, cellular, and mucosal immune responses. Our findings present a promising strategy for preparing intranasal vaccines for infectious diseases or cancer.
- Published
- 2024
- Full Text
- View/download PDF
242. Long-term effects of Omicron BA.2 breakthrough infection on immunity-metabolism balance: a 6-month prospective study.
- Author
-
Li Y, Qin S, Dong L, Qiao S, Wang X, Yu D, Gao P, Hou Y, Quan S, Li Y, Fan F, Zhao X, Ma Y, and Gao GF
- Subjects
- Humans, Prospective Studies, Proteomics, Retrospective Studies, Antibodies, Neutralizing, Antibodies, Viral, Post-Acute COVID-19 Syndrome, Breakthrough Infections
- Abstract
There have been reports of long coronavirus disease (long COVID) and breakthrough infections (BTIs); however, the mechanisms and pathological features of long COVID after Omicron BTIs remain unclear. Assessing long-term effects of COVID-19 and immune recovery after Omicron BTIs is crucial for understanding the disease and managing new-generation vaccines. Here, we followed up mild BA.2 BTI convalescents for six-month with routine blood tests, proteomic analysis and single-cell RNA sequencing (scRNA-seq). We found that major organs exhibited ephemeral dysfunction and recovered to normal in approximately six-month after BA.2 BTI. We also observed durable and potent levels of neutralizing antibodies against major circulating sub-variants, indicating that hybrid humoral immunity stays active. However, platelets may take longer to recover based on proteomic analyses, which also shows coagulation disorder and an imbalance between anti-pathogen immunity and metabolism six-month after BA.2 BTI. The immunity-metabolism imbalance was then confirmed with retrospective analysis of abnormal levels of hormones, low blood glucose level and coagulation profile. The long-term malfunctional coagulation and imbalance in the material metabolism and immunity may contribute to the development of long COVID and act as useful indicator for assessing recovery and the long-term impacts after Omicron sub-variant BTIs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
243. Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs.
- Author
-
Niu S, Zhao Z, Liu Z, Rong X, Chai Y, Bai B, Han P, Shang G, Ren J, Wang Y, Zhao X, Liu K, Tian W-x, Wang Q, and Gao GF
- Subjects
- Animals, Cricetinae, Humans, Cell Line, COVID-19 virology, Mutation, Pets metabolism, Pets virology, Protein Binding, SARS-CoV-2 chemistry, SARS-CoV-2 genetics, SARS-CoV-2 metabolism, SARS-CoV-2 ultrastructure, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus metabolism, Spike Glycoprotein, Coronavirus ultrastructure, Angiotensin-Converting Enzyme 2 chemistry, Angiotensin-Converting Enzyme 2 metabolism, Angiotensin-Converting Enzyme 2 ultrastructure, Cricetulus metabolism, Cricetulus virology, Cryoelectron Microscopy, Host Specificity, Mesocricetus metabolism, Mesocricetus virology
- Abstract
Pet golden hamsters were first identified being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant of concern (VOC) and transmitted the virus back to humans in Hong Kong in January 2022. Here, we studied the binding of two hamster (golden hamster and Chinese hamster) angiotensin-converting enzyme 2 (ACE2) proteins to the spike protein receptor-binding domains (RBDs) of SARS-CoV-2 prototype and eight variants, including alpha, beta, gamma, delta, and four omicron sub-variants (BA.1, BA.2, BA.3, and BA.4/BA.5). We found that the two hamster ACE2s present slightly lower affinity for the RBDs of all nine SARS-CoV-2 viruses tested than human ACE2 (hACE2). Furthermore, the similar infectivity to host cells expressing hamster ACE2s and hACE2 was confirmed with the nine pseudotyped SARS-CoV-2 viruses. Additionally, we determined two cryo-electron microscopy (EM) complex structures of golden hamster ACE2 (ghACE2)/delta RBD and ghACE2/omicron BA.3 RBD. The residues Q34 and N82, which exist in many rodent ACE2s, are responsible for the lower binding affinity of ghACE2 compared to hACE2. These findings suggest that all SARS-CoV-2 VOCs may infect hamsters, highlighting the necessity of further surveillance of SARS-CoV-2 in these animals.IMPORTANCESARS-CoV-2 can infect many domestic animals, including hamsters. There is an urgent need to understand the binding mechanism of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants to hamster receptors. Herein, we showed that two hamster angiotensin-converting enzyme 2s (ACE2s) (golden hamster ACE2 and Chinese hamster ACE2) can bind to the spike protein receptor-binding domains (RBDs) of SARS-CoV-2 prototype and eight variants and that pseudotyped SARS-CoV-2 viruses can infect hamster ACE2-expressing cells. The binding pattern of golden hamster ACE2 to SARS-CoV-2 RBDs is similar to that of Chinese hamster ACE2. The two hamster ACE2s present slightly lower affinity for the RBDs of all nine SARS-CoV-2 viruses tested than human ACE2. We solved the cryo-electron microscopy (EM) structures of golden hamster ACE2 in complex with delta RBD and omicron BA.3 RBD and found that residues Q34 and N82 are responsible for the lower binding affinity of ghACE2 compared to hACE2. Our work provides valuable information for understanding the cross-species transmission mechanism of SARS-CoV-2., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
244. Publisher Correction: Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus.
- Author
-
Wang H, Yin P, Zheng T, Qin L, Li S, Han P, Qu X, Wen J, Ding H, Wu J, Kong T, Gao Z, Hu S, Zhao X, Cao X, Fang M, Qi J, Xi JJ, Duan K, Yang X, Zhang Z, Wang Q, Tan W, and Gao GF
- Published
- 2024
- Full Text
- View/download PDF
245. Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus.
- Author
-
Wang H, Yin P, Zheng T, Qin L, Li S, Han P, Qu X, Wen J, Ding H, Wu J, Kong T, Gao Z, Hu S, Zhao X, Cao X, Fang M, Qi J, Xi JJ, Duan K, Yang X, Zhang Z, Wang Q, Tan W, and Gao GF
- Subjects
- Animals, Mice, Viral Envelope Proteins, Antibodies, Viral, Vaccinia virus, Antigens, Viral, Immunity, Monkeypox virus, Vaccines
- Abstract
The global outbreak of the mpox virus (MPXV) in 2022 highlights the urgent need for safer and more accessible new-generation vaccines. Here, we used a structure-guided multi-antigen fusion strategy to design a 'two-in-one' immunogen based on the single-chain dimeric MPXV extracellular enveloped virus antigen A35 bivalently fused with the intracellular mature virus antigen M1, called DAM. DAM preserved the natural epitope configuration of both components and showed stronger A35-specific and M1-specific antibody responses and in vivo protective efficacy against vaccinia virus (VACV) compared to co-immunization strategies. The MPXV-specific neutralizing antibodies elicited by DAM were 28 times higher than those induced by live VACV vaccine. Aluminum-adjuvanted DAM vaccines protected mice from a lethal VACV challenge with a safety profile, and pilot-scale production confirmed the high yield and purity of DAM. Thus, our study provides innovative insights and an immunogen candidate for the development of alternative vaccines against MPXV and other orthopoxviruses., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
246. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
- Author
-
Rao X, Zhao R, Tong Z, Guo S, Peng W, Liu K, Li S, Wu L, Tong J, Chai Y, Han P, Wang F, Jia P, Li Z, Zhao X, Li D, Zhang R, Zhang X, Zou W, Li W, Wang Q, Gao GF, Wu Y, Dai L, and Gao F
- Subjects
- Humans, COVID-19 Vaccines, Antibodies, Monoclonal, Epitopes, Antibodies, Neutralizing, Antibodies, Viral, Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19
- Abstract
Currently, monoclonal antibodies (MAbs) targeting the SARS-CoV-2 receptor binding domain (RBD) of spike (S) protein are classified into seven classes based on their binding epitopes. However, most of these antibodies are seriously impaired by SARS-CoV-2 Omicron and its subvariants, especially the recent BQ.1.1, XBB and its derivatives. Identification of broadly neutralizing MAbs against currently circulating variants is imperative. In this study, we identified a "breathing" cryptic epitope in the S protein, named as RBD-8. Two human MAbs, BIOLS56 and IMCAS74, were isolated recognizing this epitope with broad neutralization abilities against tested sarbecoviruses, including SARS-CoV, pangolin-origin coronaviruses, and all the SARS-CoV-2 variants tested (Omicron BA.4/BA.5, BQ.1.1, and XBB subvariants). Searching through the literature, some more RBD-8 MAbs were defined. More importantly, BIOLS56 rescues the immune-evaded antibody, RBD-5 MAb IMCAS-L4.65, by making a bispecific MAb, to neutralize BQ.1 and BQ.1.1, thereby producing an MAb to cover all the currently circulating Omicron subvariants. Structural analysis reveals that the neutralization effect of RBD-8 antibodies depends on the extent of epitope exposure, which is affected by the angle of antibody binding and the number of up-RBDs induced by angiotensin-converting enzyme 2 binding. This cryptic epitope which recognizes non- receptor binding motif (non-RBM) provides guidance for the development of universal therapeutic antibodies and vaccines against COVID-19., Competing Interests: Competing interests statement:The authors declare no competing interest.
- Published
- 2023
- Full Text
- View/download PDF
247. Antibody response assessment of immediate breakthrough infections after zero-COVID policy adjustment in China.
- Author
-
Li Y, Qiao S, Dong L, Zhang R, Li R, Qin S, Yu D, Liu X, Li Y, Ma Y, Zhao X, and Gao GF
- Abstract
Competing Interests: G.F.G. are listed in the patent as the inventors of the RBD-dimer as a betacoronavirus vaccine (ZF2001). All other authors declare no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
248. Evaluation and Mechanistic Investigation of Human Milk Oligosaccharide against SARS-CoV-2.
- Author
-
Yu W, Li Y, Liu D, Wang Y, Li J, Du Y, Gao GF, Li Z, Xu Y, and Wei J
- Subjects
- Humans, SARS-CoV-2, Molecular Docking Simulation, Oligosaccharides pharmacology, Oligosaccharides analysis, Antiviral Agents pharmacology, Milk, Human chemistry, COVID-19
- Abstract
Four human milk oligosaccharides (HMOs), 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), 2'-fucosyllactose (2'-FL), and 3-fucosyllactose (3-FL), were assessed for their possible antiviral activity against the SARS-CoV-2 spike receptor binding domain (RBD) in vitro . Among them, only 2'-FL/3-FL exhibited obvious antibinding activity against direct binding and trans -binding in competitive immunocytochemistry and enzyme-linked immunosorbent assays. The antiviral effects of 2'-FL/3-FL were further confirmed by pseudoviral assays with three SARS-Cov-2 mutants, with a stronger inhibition effect of 2'-FL than 3-FL. Then, 2'-FL/3-FL were studied with molecular docking and microscale thermophoresis analysis, showing that the binding sites of 2'-FL on RBD were involved in receptor binding, in addition to a tighter bond between them, thus enabling 2'-FL to be more effective than 3-FL. Moreover, the immunomodulation effect of 2'-FL was preliminary evaluated and confirmed in a human alveolus chip. These results would open up possible applications of 2'-FL for the prevention of SARS-CoV-2 infections by competitive binding inhibition.
- Published
- 2023
- Full Text
- View/download PDF
249. A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery.
- Author
-
Wu L, Zheng A, Tang Y, Chai Y, Chen J, Cheng L, Hu Y, Qu J, Lei W, Liu WJ, Wu G, Zeng S, Yang H, Wang Q, and Gao GF
- Subjects
- Humans, Animals, Mice, SARS-CoV-2, Administration, Intranasal, Amino Acid Sequence, Peptides pharmacology, COVID-19 prevention & control
- Abstract
Coronaviruses (CoVs) have brought serious threats to humans, particularly severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), which continually evolves into multiple variants. These variants, especially Omicron, reportedly escape therapeutic antibodies and vaccines, indicating an urgent need for new antivirals with pan-SARS-CoV-2 inhibitory activity. We previously reported that a peptide fusion inhibitor, P3, targeting heptad repeated-1 (HR1) of SARS-CoV-2 spike (S) protein, could inhibit viral infections. Here, we further designed multiple derivatives of the P3 based on structural analysis and found that one derivative, the P315V3, showed the most efficient antiviral activity against SARS-CoV-2 variants and several other sarbecoviruses, as well as other human-CoVs (HCoVs). P315V3 also exhibited effective prophylactic efficacy against the SARS-CoV-2 Delta and Omicron variants in mice via intranasal administration. These results suggest that P315V3, which is in Phase II clinical trial, is promising for further development as a nasal pan-SARS-CoV-2 or pan-CoVs inhibitor to prevent or treat CoV diseases., (© 2023. Science China Press.)
- Published
- 2023
- Full Text
- View/download PDF
250. Thoughts on group A streptococci.
- Author
-
Yu D, Liang Y, Lu Q, Zheng Y, Gao GF, and Yang Y
- Subjects
- Streptococcus pyogenes
- Abstract
Competing Interests: We declare no competing interests. This research was funded by the Shenzhen Key Medical Discipline Construction Fund (SZXK032), the Guangdong Medical Research Fund (A2021437), the Hospital Level Project of Shenzhen Children's Hospital (ynkt2020-zz19), the Project of the Expert Committee on Clinical Application and Drug Resistance Evaluation of Antimicrobial Drugs of the National Health Commission (KJYWZWH-OT-02-2021-06), and the Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (SZGSP012). DY, YL, and QL contributed equally.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.